Kyverna Therapeutics Future Growth
Future criteria checks 2/6
Kyverna Therapeutics's earnings are forecast to decline at 26.9% per annum while its annual revenue is expected to grow at 33% per year. EPS is expected to grow by 18.4% per annum. Return on equity is forecast to be -957.3% in 3 years.
Key information
-26.9%
Earnings growth rate
18.4%
EPS growth rate
| Biotechs earnings growth | 29.1% |
| Revenue growth rate | 33.0% |
| Future return on equity | -957.3% |
| Analyst coverage | Low |
| Last updated | 31 Jul 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 6 | -237 | -241 | -210 | 4 |
| 12/31/2025 | 4 | -181 | -200 | -159 | 5 |
| 12/31/2024 | 3 | -129 | -126 | -109 | 5 |
| 3/31/2024 | N/A | -76 | -68 | -66 | N/A |
| 12/31/2023 | N/A | -60 | -53 | -52 | N/A |
| 9/30/2023 | 0 | -48 | -43 | -43 | N/A |
| 12/31/2022 | 7 | -29 | -37 | -36 | N/A |
| 12/31/2021 | 6 | -26 | -23 | -22 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: KYTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: KYTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: KYTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: KYTX's revenue (33% per year) is forecast to grow faster than the US market (8.5% per year).
High Growth Revenue: KYTX's revenue (33% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: KYTX is forecast to be unprofitable in 3 years.